Presentation description

In preclinical models of Alzheimer's disease, our team evaluated the use of a brain-targeting peptide conjugated with low-dose paclitaxel. The compound alleviated cognitive decline more effectively than intranasal generic PTX, suggesting great translational promise for Alzheimer's disease and other CNS diseases.